Immunome’s acquired gamma secretase inhibitor, varegacestat, has demonstrated its efficacy and tolerability in a Phase III study, meaning the company will now file for the drug’s approval with the FDA ...
Annual Meeting, held on 6-9 December, results from the global, multicentre, open-label, randomised, Phase III EPCORE FL-1 ...
Dyne Therapeutics reported six-month and 24-month data from the Phase I/II trial. Image credit: Sheldon Cooper / SOPA Images / LightRocket via Getty Images. Dyne Therapeutics is seeking US accelerated ...
Capricor’s stock shot up by 371% after it announced the HOPE-3 data. Image credit: Lightspring / Shutterstock.com. Capricor Therapeutics’ stock has soared by more than 370% after a pivotal trial of ...
The new pathway was announced by FDA commissioner Martin Makary and CBER director Vinay Prasad in a New England Journal of Medicine article. Image credit: Net Vector / Shutterstock.com. The US Food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback